C12N 2760/20011
Rhabdoviridae
C12N2760/20011 (Rhabdoviridae) appears on 620 US grants and 906 published applications in this corpus.
Search patents in C12N- Granted patents
- 620
- Published applications
- 906
- Assignees
- 444
- Inventors
- 1,679
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 5 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 4 | 0 |
| 1987 | 9 | 0 |
| 1988 | 4 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 7 | 0 |
| 1993 | 3 | 0 |
| 1994 | 5 | 0 |
| 1995 | 3 | 0 |
| 1996 | 9 | 0 |
| 1997 | 8 | 0 |
| 1998 | 25 | 0 |
| 1999 | 12 | 0 |
| 2000 | 13 | 0 |
| 2001 | 20 | 5 |
| 2002 | 13 | 10 |
| 2003 | 12 | 29 |
| 2004 | 11 | 15 |
| 2005 | 3 | 17 |
| 2006 | 12 | 14 |
| 2007 | 10 | 21 |
| 2008 | 5 | 22 |
| 2009 | 9 | 23 |
| 2010 | 13 | 31 |
| 2011 | 15 | 32 |
| 2012 | 18 | 29 |
| 2013 | 13 | 28 |
| 2014 | 20 | 35 |
| 2015 | 21 | 32 |
| 2016 | 20 | 27 |
| 2017 | 31 | 45 |
| 2018 | 31 | 28 |
| 2019 | 34 | 42 |
| 2020 | 35 | 46 |
| 2021 | 19 | 52 |
| 2022 | 25 | 47 |
| 2023 | 28 | 59 |
| 2024 | 23 | 98 |
| 2025 | 41 | 68 |
| 2026 | 15 | 51 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/20211VesiculovirusIndexing code309
- C12N 2760/20111LyssavirusIndexing code265
- C12N 2760/20022New viral proteins or individual genes, new structural or functional aspects ofIndexing code43
- C12N 2760/20034Use of virus or viral component as vaccineIndexing code26
- C12N 2760/20041Use of virus, viral particle or viral elements as a vectorIndexing code24
- C12N 2760/20021Viruses as suchIndexing code17
- C12N 2760/20032Use of virus as therapeutic agent, other than vaccineIndexing code13
- C12N 2760/20051Methods of production or purification of viral materialIndexing code13
All 14 subgroupsShow fewer
- C12N 2760/20023Virus like particles [vlp]Indexing code9
- C12N 2760/20061Methods of inactivation or attenuationIndexing code6
- C12N 2760/20031Uses of virus other than therapeutic or vaccineIndexing code5
- C12N 2760/20071Demonstrated in vivo effectIndexing code4
- C12N 2760/20033Use of viral protein as therapeutic agent other than vaccineIndexing code0
- C12N 2760/20088For redistributionIndexing code0
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Influenza virus encoding a truncated NS1 protein and a SARS-CoV receptor binding domain18 Aug 2026US 12,708,663 B2Vivaldi Biosciences Inc.
- Antioxidant culture method and antioxidant auxiliary equipment11 Aug 2026US 12,703,924 B2National Pingtung University of Science and Technology
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- Purification of viruses and viral like particles8 Oct 2026US 2026/0308616 A1Interius Biotherapeutics, Inc.
- Cell surface engineered of tailored therapeutic gene delivery8 Oct 2026US 2026/0308617 A1The Children’s Hospital of Philadelphia
- Modular re-targeting of rhabdoviral (g) glycoproteins from their natural receptors24 Sep 2026US 2026/0285912 A1Vyriad, Inc.
- Vector production24 Sep 2026US 2026/0286391 A1Fondazione Telethon Ets
- Pseudotyped retroviral vector particle with anti-cd3 display24 Sep 2026US 2026/0286392 A1Miltenyi Biotec GmbH
Most cited
By later US patents
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- DNA-based vaccination of fish162US 5,780,448 AOttawa Civic Hospital Loeb Research · 1998
- Recombinant infectious non-segmented negative strand RNA virus156US 6,033,886 A2000
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996